Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
Read the digital edition!
ViiV applies for FDA approval of HIV drug fostemsavir
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
Fostemsavir offers HIV treatment hope to those with no other options.
In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.
Early results from an ongoing trial show that 24 weeks after adding the drug to their HIV regimen, half were virally suppressed.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for those with multidrug-resistant virus.
In a Phase III trial, participants responded well to the addition of biweekly injections of the cloned antibody ibalizumab.
“We need drugs that are gentler, kinder, better and cheaper.”
ViiV Healthcare recently acquired Bristol-Myers Squibb’s (BMS) portfolio of HIV antiretrovirals (ARVs) in the pipeline.
The sale includes an HIV attachment inhibitor called fostemsavir and a maturation inhibitor, both in late-stage development.
The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.